|
1
|
Wu H, Lin W and Tsai K: Advances in
molecular biomarkers for gastric cancer: miRNAs as emerging novel
cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fang WL, Huang KH, Lan YT, Lin CH, Chang
SC, Chen MH, Chao Y, Lin WC, Lo SS, Li AF, et al: Mutations in
PI3K/AKT pathway genes and amplifications of PIK3CA are associated
with patterns of recurrence in gastric cancers. Oncotarget.
7:6201–6220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Camargo MC, Kim K, Matsuo K, Torres J,
Liao LM, Morgan DR, Michel A, Waterboer T, Zabaleta J, Dominguez
RL, et al: Anti-Helicobacter pylori antibody profiles in
epstein-Barr virus (EBV)-positive and EBV-negative gastric cancer.
Helicobacter. 21:153–157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Camargo MC, Bowlby R, Chu A, Pedamallu CS,
Thorsson V, Elmore S, Mungall AJ, Bass AJ, Gulley ML and Rabkin CS:
Validation and calibration of next-generation sequencing to
identify Epstein-Barr virus-positive gastric cancer in The cancer
genome atlas. Gastric Cancer. 19:676–681. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Yang W, Pan Y, Ji J, Lu Z and Ke Y:
Genome-wide analysis of Epstein-Barr virus (EBV) isolated from
EBV-associated gastric carcinoma (EBVaGC). Oncotarget. 7:4903–4914.
2016.PubMed/NCBI
|
|
6
|
Zhang L, Wang C, Yu S, Jia C, Yan J, Lu Z
and Chen J: Loss of ARID1A expression correlates with tumor
differentiation and tumor progression stage in pancreatic ductal
adenocarcinoma. Technol Cancer ResTreat. 17:1–10. 2018.
|
|
7
|
Wang S, Nassour I, Xiao S, Zhang S, Luo X,
Lee J, Li L, Sun X, Nguyen LH, Chuang JC, et al: SWI/SNF component
ARID1A restrains pancreatic neoplasia formation. Pancreas.
doi:10.1136/gutjnl-2017-315490.
|
|
8
|
Shen J, Peng Y, Wei L, Zhang W, Yang L,
Lan L, Kapoor P, Ju Z, Mo Q, Shih IM, et al: ARID1A deficiency
impairs the DNA damage checkpoint and sensitizes cells to PARP
inhibitors. Cancer Discov. 5:752–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mathur R, Alver BH, San Roman AK, Wilson
BG, Wang X, Agoston AT, Park PJ, Shivdasani RA and Roberts CW:
ARID1A loss impairs enhancer-mediated gene regulation and drives
colon cancer in mice. Nat Genet. 49:296–302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abe H, Kaneda A and Fukayama M:
Epstein-Barr virus-associated gastric carcinoma: Use of host cell
machineries and somatic gene mutations. Pathobiology. 82:212–223.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang L, Shan L, Zhang S, Ying J, Xue L,
Yuan Y, Xie Y and Lu N: PIK3CA gene mutations and overexpression:
Implications for prognostic biomarker and therapeutic target in
chinese esophageal squamous cell carcinoma. PLoS One.
9:e1030212014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park JH, Ryu MH, Park YS, Park SR, Na YS,
Rhoo BY and Kang YK: Successful control of heavily pretreated
metastatic gastric cancer with the mTOR inhibitor everolimus
(RAD001) in a patient with PIK3CA mutation and pS6 overexpression.
BMC Cancer. 15:1192015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Q, Shi YL, Zhou K, Wang LL, Yan ZX,
Liu YL, Xu LL, Zhao SW, Chu HL, Shi TT, et al: PIK3CA mutation
confer resistance to first-line chemotherapy in colorectal cancer.
Cell Death Dis. 9:7392018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Hong, Tan Shun, Xing Lu, Li Qian and
Zhou Huan: Expression and significance of EBV, ARID1A and PIK3CA
gene in gastric cancer. Hainan Med J. 29:1344–1347. 2018.
|
|
15
|
Liu P, Qin K, Wu K, Shi H and Zhang L: The
expression and significance of HAND2 in the myenteric plexus of the
colon in patients with Hirschsprung's disease. Guangdong Med J.
34:1513–1515. 2013.(In Chinese).
|
|
16
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan ASY, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes of
gastric cancer. Nature Genetics. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanda T, Furuse Y, Oshitani H and Kiyono
T: Highly efficient CRISPR/Cas9-mediated cloning and functional
characterization of gastric cancer-Derived epstein-Barr virus
strains. J Virol. 90:4383–4393. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang L, Wu H, Sun G, Xu X, Sun X and Cao
L: Trichloromethane fraction of Incarvillea compacta induces lytic
cytotoxicity and apoptosis in Epstein-Barr virus-positive gastric
cancer AGS cells. BMC Complem Altern Med. 16:344–354. 2016.
View Article : Google Scholar
|
|
19
|
Gulley ML: Genomic assays for Epstein–Barr
virus-positive gastric adenocarcinoma. Exp Mol Med. 47:e1342015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang DD: Decreased expression of the
ARID1A gene Is associated with poor prognosis in primary gastric
Cancer. PLoS One. 7:e403642012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Luchini C, Veronese N, Solmi M, Cho H, Kim
J, Chou A, Gill AJ, Faraj SF, Chaux A, Netto GJ, et al: Prognostic
role and implications of mutation status of tumor suppressor gene
ARID1A in cancer: A systematic review and meta-analysis.
Oncotarget. 6:39088–39097. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harada K, Baba Y, Shigaki H, Ishimoto T,
Miyake K, Kosumi K, Tokunaga R, Izumi D, Ohuchi M, Nakamura K, et
al: Prognostic and clinical impact of PIK3CA mutation in gastric
cancer: Pyrosequencing technology and literature review. BMC
Cancer. 16:400–407. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ibarrola-Villava M, Llorca-Cardenosa MJ,
Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Rosello S,
Navarro S, Ribas G and Cervantes A: Deregulation of ARID1A, CDH1,
cMET and PIK3CA and target-related microRNA expression in gastric
cancer. Oncotarget. 6:26935–26945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jang SH, Kim KJ, Oh MH, Lee JH and Lee HJ:
Clinicopathological significance of elevated PIK3CA expression in
gastric cancer. J Gastric Cancer. 16:85–92. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu Y, Gu Y, Guo S, Dai Q and Zhang W:
Expressing status and correlation of ARID1A and histone H2B on
breast cancer. Biomed Res Int 2016. 7593872016.
|
|
26
|
Wei X, Wang DS, Xi SY, Wu WJ, Chen DL,
Zeng ZL, Wang RY, Huang YX, Jin Y, Wang F, et al: Clinicopathologic
and prognostic relevance of ARID1A protein loss in colorectal
cancer. World J Gastroenterol. 20:18404–18412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee D, Yu EJ, Ham IH, Hur H and Kim YS:
AKT inhibition is an effective treatment strategy in
ARID1A-deficient gastric cancer cells. Onco Targrts Ther.
10:4153–4159. 2017. View Article : Google Scholar
|
|
28
|
Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ,
Jiang YH, Feng L, Yang PY and Liu F: Chromatin remodeling gene
AT-rich interactive domaincontaining protein 1A suppresses gastric
cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget.
7:46127–46141. 2016.PubMed/NCBI
|
|
29
|
Giulino-Roth L, Wang K, Macdonald TY,
Mathew S, Tam Y, Cronin MT, Palmer G, Lucena-Silva N, Pedrosa F,
Pedrosa M, et al: Targeted genomic sequencing of pediatric Burkitt
lymphoma identifies recurrent alterations in antiapoptotic and
chromatin-remodeling genes. Blood. 120:5181–5184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu R, Wang T and Shih IeM: The emerging
roles of ARID1A in tumor suppression. Cancer Biol Ther. 15:655–664.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Böger C, Krüger S, Behrens HM, Bock S,
Haag J, Kalthoff H and Röcken C: Epstein-Barr virus-associated
gastric cancer reveals intratumoral heterogeneity of PIK3CA
mutations. Ann Oncol. 28:1005–1014. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kaneda A, Matsusaka K, Aburatani H and
Fukayama M: Epstein-Barr virus infection as an epigenetic driver of
tumorigenesis. Cancer Res. 72:3445–3450. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Suzuki Y, Enokido Y, Yamada K, Inaba M,
Kuwata K, Hanada N, Morishita T, Mizuno S and Wakamatsu N: The
effect of rapamycin, NVP-BEZ235, aspirin, and metforminon
PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth
spectrum (PROS). Oncotarget. 8:45470–45483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang XY, Huang YX, Guo RH, Liu YB, Qian
YY, Liu D, Dai XJ, Wei Z, Jin F and Liu YQ: Clinicopathological
significance of ROCK1 and PIK3CA expression in nasopharyngeal
carcinoma. Exp Ther Med. 13:1064–1068. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ,
Jiang YH, Feng L, Yang P Y and Liu F: Chromatin remodeling gene
AT-rich interactive domain-containing protein 1A suppresses gastric
cancer cell proliferation by targeting PIK3CA and PDK1. Oncotarget.
7:46127–46141. 2016.PubMed/NCBI
|
|
36
|
Sivachandran N, Dawson CW, Young LS, Liu
FF, Middeldorp J and Frappier L: Contributions of the epstein-Barr
virus EBNA1 protein to gastric carcinoma. J Virol. 86:60–68. 2011.
View Article : Google Scholar : PubMed/NCBI
|
